| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Matthias M Herth, Ida Nymann Petersen, Hanne Demant Hansen, Martin Hansen, Anders Ettrup, Anders A Jensen, Szabolcs Lehel, Agnete Dyssegaard, Nic Gillings, Gitte M Knudsen, Jesper L Kristense. Synthesis and evaluation of (18)F-labeled 5-HT2A receptor agonists as PET ligands. Nuclear medicine and biology. vol 43. issue 8. 2017-11-20. PMID:27209485. |
the serotonin 2a receptor (5-ht2ar) is the most abundant excitatory 5-ht receptor in the human brain and implicated in various brain disorders such as schizophrenia, depression, and alzheimer's disease. |
2017-11-20 |
2023-08-13 |
human |
| Katarzyna Grychowska, Grzegorz Satała, Tomasz Kos, Anna Partyka, Evelina Colacino, Severine Chaumont-Dubel, Xavier Bantreil, Anna Wesołowska, Maciej Pawłowski, Jean Martinez, Philippe Marin, Gilles Subra, Andrzej J Bojarski, Frédéric Lamaty, Piotr Popik, Paweł Zajde. Novel 1H-Pyrrolo[3,2-c]quinoline Based 5-HT6 Receptor Antagonists with Potential Application for the Treatment of Cognitive Disorders Associated with Alzheimer's Disease. ACS chemical neuroscience. vol 7. issue 7. 2017-10-19. PMID:27100049. |
modulators of the serotonin 5-ht6 receptor (5-ht6r) offer a promising strategy for the treatment of the cognitive deficits that are associated with dementia and alzheimer's disease. |
2017-10-19 |
2023-08-13 |
Not clear |
| Alexandre V Ivachtchenko, Yan A Ivanenkov, Mark S Veselov, I M Oku. AVN-322 is a Safe Orally Bio-Available Potent and Highly Selective Antagonist of 5-HT6R with Demonstrated Ability to Improve Impaired Memory in Animal Models. Current Alzheimer research. vol 14. issue 3. 2017-10-16. PMID:27829340. |
in recent years, 5-hydroxytryptamine subtype 6 receptor (5-ht6 receptor, 5- ht6r) has emerged as a promising therapeutic target for the treatment of neuropathological disorders, including alzheimer's disease (ad) and schizophrenia. |
2017-10-16 |
2023-08-13 |
Not clear |
| Julien Lalut, Delphine Karila, Patrick Dallemagne, Christophe Rochai. Modulating 5-HT Future medicinal chemistry. vol 9. issue 8. 2017-09-12. PMID:28504917. |
modulating 5-ht alzheimer's disease (ad) is the most common form of dementia affecting millions of patients worldwide which can only be treated with symptomatic drugs. |
2017-09-12 |
2023-08-13 |
Not clear |
| Jose Henrique Ledo, Estefania P Azevedo, Danielle Beckman, Felipe C Ribeiro, Luis E Santos, Daniela S Razolli, Grasielle C Kincheski, Helen M Melo, Maria Bellio, Antonio L Teixeira, Licio A Velloso, Debora Foguel, Fernanda G De Felice, Sergio T Ferreir. Cross Talk Between Brain Innate Immunity and Serotonin Signaling Underlies Depressive-Like Behavior Induced by Alzheimer's Amyloid-β Oligomers in Mice. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 36. issue 48. 2017-08-18. PMID:27903721. |
cross talk between brain innate immunity and serotonin signaling underlies depressive-like behavior induced by alzheimer's amyloid-β oligomers in mice. |
2017-08-18 |
2023-08-13 |
mouse |
| Lhassane Ismaili, Bernard Refouvelet, Mohamed Benchekroun, Simone Brogi, Margherita Brindisi, Sandra Gemma, Giuseppe Campiani, Slavica Filipic, Danica Agbaba, Gerard Esteban, Mercedes Unzeta, Katarina Nikolic, Stefania Butini, José Marco-Contelle. Multitarget compounds bearing tacrine- and donepezil-like structural and functional motifs for the potential treatment of Alzheimer's disease. Progress in neurobiology. vol 151. 2017-07-11. PMID:26797191. |
other targets relevant to alzheimer's disease have also been considered in the last years for producing multitarget compounds such as β-secretase, monoamino oxidases, serotonin receptors and sigma 1 receptors. |
2017-07-11 |
2023-08-13 |
Not clear |
| Amanda Calhoun, Je Ko, George T Grossber. Emerging chemical therapies targeting 5-hydroxytryptamine in the treatment of Alzheimer's disease. Expert opinion on emerging drugs. vol 22. issue 1. 2017-06-19. PMID:28253832. |
emerging chemical therapies targeting 5-hydroxytryptamine in the treatment of alzheimer's disease. |
2017-06-19 |
2023-08-13 |
Not clear |
| Katarina Varnäs, Anders Juréus, Peter Johnström, Charlotte Ahlgren, Pär Schött, Magnus Schou, Susanne Gruber, Eva Jerning, Jonas Malmborg, Christer Halldin, Lovisa Afzelius, Lars Fard. Integrated Strategy for Use of Positron Emission Tomography in Nonhuman Primates to Confirm Multitarget Occupancy of Novel Psychotropic Drugs: An Example with AZD3676. The Journal of pharmacology and experimental therapeutics. vol 358. issue 3. 2017-05-26. PMID:27402278. |
azd3676 [n,n-dimethyl-7-(4-(2-(pyridin-2-yl)ethyl)piperazin-1-yl) benzofuran-2-carboxamide] is a novel combined serotonin (5-hydroxytryptamine) 5-ht1a and 5-ht1b receptor antagonist that was developed for the treatment of cognitive impairment in alzheimer's disease. |
2017-05-26 |
2023-08-13 |
monkey |
| Wan Fu, Heng Xie, Moshe Laudon, Shouhong Zhou, Shaowen Tian, Yong Yo. Piromelatine ameliorates memory deficits associated with chronic mild stress-induced anhedonia in rats. Psychopharmacology. vol 233. issue 12. 2017-02-14. PMID:27007604. |
previous studies have demonstrated that piromelatine (a melatonin and serotonin 5-ht1a and 5-ht1d agonist) exerts an antidepressant activity in rodent models of acute stress and improves cognitive impairments in a rat model of alzheimer's disease (ad). |
2017-02-14 |
2023-08-13 |
rat |
| Anna Więckowska, Marcin Kołaczkowski, Adam Bucki, Justyna Godyń, Monika Marcinkowska, Krzysztof Więckowski, Paula Zaręba, Agata Siwek, Grzegorz Kazek, Monika Głuch-Lutwin, Paweł Mierzejewski, Przemysław Bienkowski, Halina Sienkiewicz-Jarosz, Damijan Knez, Tomasz Wichur, Stanislav Gobec, Barbara Malawsk. Novel multi-target-directed ligands for Alzheimer's disease: Combining cholinesterase inhibitors and 5-HT European journal of medicinal chemistry. vol 124. 2017-02-14. PMID:27560283. |
novel multi-target-directed ligands for alzheimer's disease: combining cholinesterase inhibitors and 5-ht as currently postulated, a complex treatment may be key to an effective therapy for alzheimer's disease (ad). |
2017-02-14 |
2023-08-13 |
Not clear |
| Rui Weng, Sensen Shen, Casey Burton, Li Yang, Honggang Nie, Yonglu Tian, Yu Bai, Huwei Li. Lipidomic profiling of tryptophan hydroxylase 2 knockout mice reveals novel lipid biomarkers associated with serotonin deficiency. Analytical and bioanalytical chemistry. vol 408. issue 11. 2016-12-13. PMID:26780709. |
consequently, serotonin deficiency is involved in a wide variety of neurodegenerative diseases, including alzheimer's disease, parkinson's disease, schizophrenia, and depression. |
2016-12-13 |
2023-08-13 |
mouse |
| Hyung-Mun Yun, Kyung-Ran Park, Eun-Cheol Kim, Sanghyeon Kim, Jin Tae Hon. Serotonin 6 receptor controls Alzheimer's disease and depression. Oncotarget. vol 6. issue 29. 2016-08-22. PMID:26449188. |
serotonin 6 receptor controls alzheimer's disease and depression. |
2016-08-22 |
2023-08-13 |
mouse |
| Rui Weng, Sensen Shen, Yonglu Tian, Casey Burton, Xinyuan Xu, Yi Liu, Cuilan Chang, Yu Bai, Huwei Li. Metabolomics Approach Reveals Integrated Metabolic Network Associated with Serotonin Deficiency. Scientific reports. vol 5. 2016-08-10. PMID:26154191. |
while serotonin deficiency has been associated with multiple pathological conditions such as depression, schizophrenia, alzheimer's disease and parkinson's disease, the serotonin-dependent mechanisms remain poorly understood. |
2016-08-10 |
2023-08-13 |
mouse |
| Sylvie Claeysen, Joël Bockaert, Patrizia Giannon. Serotonin: A New Hope in Alzheimer's Disease? ACS chemical neuroscience. vol 6. issue 7. 2016-04-19. PMID:26011650. |
serotonin: a new hope in alzheimer's disease? |
2016-04-19 |
2023-08-13 |
Not clear |
| Matthias M Herth, Gitte M Knudse. Current radiosynthesis strategies for 5-HT2A receptor PET tracers. Journal of labelled compounds & radiopharmaceuticals. vol 58. issue 7. 2016-03-29. PMID:25997728. |
serotonin 2a receptors have been implicated in various psychophysiological functions and disorders such as depression, alzheimer's disease, or schizophrenia. |
2016-03-29 |
2023-08-13 |
Not clear |
| Rui Weng, Sensen Shen, Li Yang, Min Li, Yonglu Tian, Yu Bai, Huwei Li. Lipidomic analysis of p-chlorophenylalanine-treated mice using continuous-flow two-dimensional liquid chromatography/quadrupole time-of-flight mass spectrometry. Rapid communications in mass spectrometry : RCM. vol 29. issue 16. 2016-01-25. PMID:26212164. |
although serotonin deficiency is involved with various physiological disorders such as alzheimer's disease, parkinson's disease, schizophrenia and depression, the serotonin-dependent pathomechanisms remain poorly understood, particularly from a lipidomics perspective. |
2016-01-25 |
2023-08-13 |
mouse |
| Soumya Mukherjee, Manas Seal, Somdatta Ghosh De. Kinetics of serotonin oxidation by heme-Aβ relevant to Alzheimer's disease. Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry. vol 19. issue 8. 2015-08-13. PMID:25248842. |
kinetics of serotonin oxidation by heme-aβ relevant to alzheimer's disease. |
2015-08-13 |
2023-08-13 |
Not clear |
| Soumya Mukherjee, Manas Seal, Somdatta Ghosh De. Kinetics of serotonin oxidation by heme-Aβ relevant to Alzheimer's disease. Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry. vol 19. issue 8. 2015-08-13. PMID:25248842. |
a deficit in 5-ht dependent neuronal activity is somewhat specific for alzheimer's disease. |
2015-08-13 |
2023-08-13 |
Not clear |
| Micha Milovanovic, Kristoffer Eriksson, Bengt Winblad, Staffan Nilsson, Tomas L Lindahl, Claes Post, Petter Järem. Alzheimer and platelets: low-density platelet populations reveal increased serotonin content in Alzheimer type dementia. Clinical biochemistry. vol 47. issue 15. 2015-06-11. PMID:25041722. |
alzheimer and platelets: low-density platelet populations reveal increased serotonin content in alzheimer type dementia. |
2015-06-11 |
2023-08-13 |
Not clear |
| Cédric Lecoutey, Damien Hedou, Thomas Freret, Patrizia Giannoni, Florence Gaven, Marc Since, Valentine Bouet, Céline Ballandonne, Sophie Corvaisier, Aurélie Malzert Fréon, Serge Mignani, Thierry Cresteil, Michel Boulouard, Sylvie Claeysen, Christophe Rochais, Patrick Dallemagn. Design of donecopride, a dual serotonin subtype 4 receptor agonist/acetylcholinesterase inhibitor with potential interest for Alzheimer's disease treatment. Proceedings of the National Academy of Sciences of the United States of America. vol 111. issue 36. 2015-04-20. PMID:25157130. |
design of donecopride, a dual serotonin subtype 4 receptor agonist/acetylcholinesterase inhibitor with potential interest for alzheimer's disease treatment. |
2015-04-20 |
2023-08-13 |
Not clear |